These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20978164)

  • 1. SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeutics.
    Basso AD; Liu M; Dai C; Gray K; Nale L; Tevar S; Lee S; Liang L; Ponery A; Yaremko B; Smith E; Tang H; Sheth PR; Siddiqui MA; Hicklin DJ; Kirschmeier P
    Mol Cancer Ther; 2010 Nov; 9(11):2993-3002. PubMed ID: 20978164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel spiro 1,3,4-thiadiazolines as potent, orally bioavailable and brain penetrant KSP inhibitors.
    Mansoor UF; Angeles AR; Dai C; Yang L; Vitharana D; Basso AD; Gray K; Tang H; Liu M; Liang L; Allbritton O; Siddiqui MA
    Bioorg Med Chem; 2015 May; 23(10):2424-34. PubMed ID: 25868746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells.
    Nakai R; Iida S; Takahashi T; Tsujita T; Okamoto S; Takada C; Akasaka K; Ichikawa S; Ishida H; Kusaka H; Akinaga S; Murakata C; Honda S; Nitta M; Saya H; Yamashita Y
    Cancer Res; 2009 May; 69(9):3901-9. PubMed ID: 19351824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCH 1473759, a novel Aurora inhibitor, demonstrates enhanced anti-tumor activity in combination with taxanes and KSP inhibitors.
    Basso AD; Liu M; Gray K; Tevar S; Lee S; Liang L; Ponery A; Smith EB; Monsma FJ; Yu T; Zhang Y; Kerekes AD; Esposite S; Xiao Y; Tagat JR; Hicklin DJ; Kirschmeier P
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):923-33. PubMed ID: 21298383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of a kinesin inhibitor.
    Sakowicz R; Finer JT; Beraud C; Crompton A; Lewis E; Fritsch A; Lee Y; Mak J; Moody R; Turincio R; Chabala JC; Gonzales P; Roth S; Weitman S; Wood KW
    Cancer Res; 2004 May; 64(9):3276-80. PubMed ID: 15126370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.
    LoRusso PM; Goncalves PH; Casetta L; Carter JA; Litwiler K; Roseberry D; Rush S; Schreiber J; Simmons HM; Ptaszynski M; Sausville EA
    Invest New Drugs; 2015 Apr; 33(2):440-9. PubMed ID: 25684345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in the identification and clinical evaluation of inhibitors of the mitotic kinesin KSP.
    Knight SD; Parrish CA
    Curr Top Med Chem; 2008; 8(10):888-904. PubMed ID: 18673173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models.
    Ye XS; Fan L; Van Horn RD; Nakai R; Ohta Y; Akinaga S; Murakata C; Yamashita Y; Yin T; Credille KM; Donoho GP; Merzoug FF; Li H; Aggarwal A; Blanchard K; Westin EH
    Mol Cancer Ther; 2015 Nov; 14(11):2463-72. PubMed ID: 26304237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs.
    Cox CD; Garbaccio RM
    Anticancer Agents Med Chem; 2010 Nov; 10(9):697-712. PubMed ID: 21235439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520.
    Tunquist BJ; Woessner RD; Walker DH
    Mol Cancer Ther; 2010 Jul; 9(7):2046-56. PubMed ID: 20571074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel ATP-competitive kinesin spindle protein inhibitors.
    Parrish CA; Adams ND; Auger KR; Burgess JL; Carson JD; Chaudhari AM; Copeland RA; Diamond MA; Donatelli CA; Duffy KJ; Faucette LF; Finer JT; Huffman WF; Hugger ED; Jackson JR; Knight SD; Luo L; Moore ML; Newlander KA; Ridgers LH; Sakowicz R; Shaw AN; Sung CM; Sutton D; Wood KW; Zhang SY; Zimmerman MN; Dhanak D
    J Med Chem; 2007 Oct; 50(20):4939-52. PubMed ID: 17725339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models.
    Woessner R; Tunquist B; Lemieux C; Chlipala E; Jackinsky S; Dewolf W; Voegtli W; Cox A; Rana S; Lee P; Walker D
    Anticancer Res; 2009 Nov; 29(11):4373-80. PubMed ID: 20032381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin KSP.
    Liu F; Yu LQ; Jiang C; Yang L; Wu WT; You QD
    Bioorg Med Chem; 2010 Jun; 18(12):4167-77. PubMed ID: 20537544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer.
    Purcell JW; Davis J; Reddy M; Martin S; Samayoa K; Vo H; Thomsen K; Bean P; Kuo WL; Ziyad S; Billig J; Feiler HS; Gray JW; Wood KW; Cases S
    Clin Cancer Res; 2010 Jan; 16(2):566-76. PubMed ID: 20068098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage.
    Tao W; South VJ; Zhang Y; Davide JP; Farrell L; Kohl NE; Sepp-Lorenzino L; Lobell RB
    Cancer Cell; 2005 Jul; 8(1):49-59. PubMed ID: 16023598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy.
    Song H; Zhou S; Wang R; Li S
    ChemMedChem; 2013 Nov; 8(11):1736-49. PubMed ID: 23964020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the kinesin spindle protein: basic principles and clinical implications.
    Sarli V; Giannis A
    Clin Cancer Res; 2008 Dec; 14(23):7583-7. PubMed ID: 19047082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinesin spindle protein inhibitors in cancer: a patent review (2008 - present).
    Jiang C; You Q
    Expert Opin Ther Pat; 2013 Dec; 23(12):1547-60. PubMed ID: 23978071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developments of kinesin spindle protein inhibitors as antitumor agents based on the five-membered heterocycle scaffolds.
    Zhao GD; Wan RZ; Liu ZP
    Curr Med Chem; 2014; 21(23):2691-701. PubMed ID: 24606497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinesin spindle protein inhibitor SB743921 induces mitotic arrest and apoptosis and overcomes imatinib resistance of chronic myeloid leukemia cells.
    Yin Y; Sun H; Xu J; Xiao F; Wang H; Yang Y; Ren H; Wu CT; Gao C; Wang L
    Leuk Lymphoma; 2015 Jun; 56(6):1813-20. PubMed ID: 25146433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.